Describe the mutation that confers resistance to infection to a major strain of HIV.

BIKTARVY® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY.

asfe afr dsef rfdg fghgnts fhbfgd   hdfdx

a covalent bond, specfically triple bond